Article Text

other Versions

PDF
Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis
  1. Adriana Céspedes-Cruz (ivonneadri{at}hotmail.com)
  1. Centro Medico Nacional La Raza, Mexico
    1. Raúl Gutiérrez-Suárez (rgtzs{at}prodigy.net.mx)
    1. Hospital General de México, Research Division, Mexico
      1. Angela Pistorio (angelapistorio{at}ospedale-gaslini.ge.it)
      1. Istituto G. Gaslini, Italy
        1. Angelo Ravelli (angeloravelli{at}ospedale-gaslini.ge.it)
        1. Istituto G. Gaslini, Italy
          1. Anna Loy (annaloy{at}ospedale-gaslini.ge.it)
          1. Istituto G. Gaslini, Italy
            1. Kevin J Murray (kevin.murray{at}health.wa.gov.au)
            1. Princess Margaret Hospital for Children, Australia
              1. Valeria Gerloni (gerloni{at}gpini.it)
              1. Gaetano Pini Institute of orthopedic, Italy
                1. Nico M Wulffraat (n.wulffraat{at}umcutrecht.nl)
                1. University Medical Center Utrecht, Netherlands
                  1. Sheila Oliveira (sheila_knupp{at}hotmail.com)
                  1. Instituto de Puericultura e Pediatria Martagao Gesteira, Brazil
                    1. Jo Walsh (jo.walsh{at}rah.scot.nhs.uk)
                    1. Royal Alexandra Hospital, United Kingdom
                      1. Immaculada Calvo Penades (calvo_inm{at}gva.es)
                      1. Hospital Universitario La Fe, Spain
                        1. Maria Giannina Alpigiani (gianninaalpigiani{at}ospedale-gaslini.ge.it)
                        1. Istituto G. Gaslini, Italy
                          1. Pekka Lahdenne (pekka.lahdenne{at}hus.fi)
                          1. University of Helsinki, Finland
                            1. Claudia Saad-Magalhães (claudi{at}fmb.unesp.br)
                            1. Faculdade de Medicina de Botucatu, Universidade Estadual Paulista, Brazil
                              1. Elisabetta Cortis (cortis{at}opbg.net)
                              1. Ospedale Pediatrico Bambin Gesù, Italy
                                1. Loredana Lepore (leporel{at}burlo.trieste.it)
                                1. Universita' degli Studi di Trieste, Italy
                                  1. Yukiko Kimura (ykimura{at}humed.com)
                                  1. Hackensack Medical Center, United States
                                    1. Carine Wouters (carine.wouters{at}uz.kuleuven.ac.be)
                                    1. University Hospital Gasthuisberg, Belgium
                                      1. Alberto Martini (albertomartini{at}ospedale-gaslini.ge.it)
                                      1. University of Genoa, Italy
                                        1. Nicolino Ruperto (nicolaruperto{at}ospedale-gaslini.ge.it)
                                        1. IRCCS G. Gaslini, Italy

                                          Abstract

                                          Objectives: To examine the change in health-related quality of life (HRQOL) and its determinants in children with juvenile idiopathic arthritis (JIA) treated with methotrexate (MTX).

                                          Methods: Patients were extracted from the PRINTO clinical trial aimed to evaluate the efficacy and safety profile of MTX administered in standard, intermediate or higher doses (10, 15 and 30 mg/m2/week respectively). Children with polyarticular-course JIA, who were less than 18 years and had a complete HRQOL assessment were included.

                                          Results: A total of 521 children were included. At baseline, JIA patients showed poorer HRQOL (p<0.01) as compared to healthy children. In 207/412 (50%) and 63 (15%) children, HRQOL values were 2 standard deviation from the mean of healthy controls in the physical and psychosocial summary scale, respectively. After 6 months of therapy with standard-dose MTX, there was a statistical significant improvement in all HRQOL health concepts, particularly in the physical ones. Similar improvements were observed in the patients non-responders to standard dose MTX who were subsequently randomized to higher dose-MTX. The presence of marked disability at baseline was associated with a 5-fold increased risk to maintain a poor physical health after 6 months of active treatment with standard-dose MTX. Other less important determinants for maintenance of poor physical well being were the baseline level of systemic inflammation, the intensity of child’s pain and an ANA-negative status.

                                          Conclusions: We report that MTX treatment produces a significant improvement across a wide range of HRQOL components, particularly in the physical domains, in patients with JIA.

                                          • health related quality of life
                                          • juvenile idiopathic arthritis
                                          • methotrexate

                                          Statistics from Altmetric.com

                                          Request permissions

                                          If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.